Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam
G Singh, S Lanes, G Triadafilopoulos - The American journal of medicine, 2004 - Elsevier
PURPOSE: To assess the risk of serious gastrointestinal and thromboembolic complications
with approved doses of meloxicam. METHODS: We pooled data from clinical trials of
meloxicam at doses of 7.5 or 15 mg/d. A blinded gastrointestinal adjudication committee
used prespecified criteria to identify gastric or duodenal perforation, gastric outlet
obstruction, or hemodynamically important upper gastrointestinal bleeding. For analysis of
thromboembolic complications, investigator-reported events were analyzed without …
with approved doses of meloxicam. METHODS: We pooled data from clinical trials of
meloxicam at doses of 7.5 or 15 mg/d. A blinded gastrointestinal adjudication committee
used prespecified criteria to identify gastric or duodenal perforation, gastric outlet
obstruction, or hemodynamically important upper gastrointestinal bleeding. For analysis of
thromboembolic complications, investigator-reported events were analyzed without …